• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Davidson Michael H.

    6/9/25 4:42:59 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Davidson Michael H.

    (Last) (First) (Middle)
    C/O BIOAGE LABS, INC.
    5885 HOLLIS STREET, SUITE 370

    (Street)
    EMERYVILLE CA 94608

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioAge Labs, Inc. [ BIOA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $4.44 06/05/2025 A 22,000 (1) 06/04/2035 Common Stock 22,000 $0 22,000 D
    Explanation of Responses:
    1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
    /s/ Dov A. Goldstein as attorney-in-fact 06/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIOA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    1/27/2026$73.00Overweight
    Piper Sandler
    12/5/2025$12.00Underweight → Equal-Weight
    Morgan Stanley
    10/22/2025$10.00Neutral → Buy
    Citigroup
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    More analyst ratings

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rubin Paul D exercised 7,433 shares at a strike of $4.77 and sold $139,369 worth of shares (7,433 units at $18.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    2/3/26 4:26:11 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldstein Dov A Md exercised 3,541 shares at a strike of $4.38, increasing direct ownership by 14% to 29,491 units (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    2/3/26 4:23:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 16% to 25,950 units (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    1/21/26 4:20:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Announces Pricing of Upsized $115.0 Million Public Offering

    EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfact

    1/21/26 10:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Announces Proposed Public Offering

    EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to mar

    1/20/26 4:01:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

    BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers including hsCRP, IL-6, and IL-1β Proof-of-concept trial in DME is designed to demonstrate ocular target engagement, supporting future development across inflammation-driven retinal diseases DME tri

    1/20/26 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on BioAge Labs with a new price target

    Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00

    1/27/26 8:43:35 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded BioAge Labs from Underweight to Equal-Weight and set a new price target of $12.00

    12/5/25 1:35:23 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Citigroup with a new price target

    Citigroup upgraded BioAge Labs from Neutral to Buy and set a new price target of $10.00

    10/22/25 7:00:32 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    SEC Form 144 filed by BioAge Labs Inc.

    144 - BioAge Labs, Inc. (0001709941) (Subject)

    2/2/26 9:43:14 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioAge Labs, Inc. (0001709941) (Filer)

    1/22/26 4:34:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BioAge Labs Inc.

    424B5 - BioAge Labs, Inc. (0001709941) (Filer)

    1/22/26 4:32:42 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care